- AutorIn
- Annika Schlamann
- André von Bueren
- Christian Hagel
- Isabella Zwiener
- Clemens Seidel
- Rolf-Dieter Kortmann
- Klaus Müller
- Titel
- An individual patient data meta-analysis on characteristics and outcome of patients with papillary glioneuronal tumor, rosette glioneuronal tumor with neuropil-like islands and rosette forming glioneuronal tumor of the fourth ventricle
- Zitierfähige Url:
- https://nbn-resolving.org/urn:nbn:de:bsz:15-qucosa-148338
- Quellenangabe
- Cell Death and Disease (2014) 5, e1119; doi:10.1038/cddis.2014.25
- Erstveröffentlichung
- 2014
- Abstract (DE)
- Background and Purpose: In 2007, the WHO classification of brain tumors was extended by three new entities of glioneuronal tumors: papillary glioneuronal tumor (PGNT), rosette-forming glioneuronal tumor of the fourth ventricle (RGNT) and glioneuronal tumor with neuropil-like islands (GNTNI). Focusing on clinical characteristics and outcome, the authors performed a comprehensive individual patient data (IPD) meta-analysis of the cases reported in literature until December 2012. Methods: PubMed, Embase and Web of Science were searched for peer-reviewed articles reporting on PGNT, RGNT, and GNTNI using predefined keywords. Results: 95 publications reported on 182 patients (PGNT, 71; GNTNI, 26; RGNT, 85). Median age at diagnosis was 23 years (range 4–75) for PGNT, 27 years (range 6–79) for RGNT, and 40 years (range 2–65) for GNTNI. Ninety-seven percent of PGNT and 69% of GNTNI were located in the supratentorial region, 23% of GNTNI were in the spinal cord, and 80% of RGNT were localized in the posterior fossa. Complete resection was reported in 52 PGNT (73%), 36 RGNT (42%), and 7 GNTNI (27%) patients. Eight PGNT, 3 RGNT, and 12 GNTNI patients were treated with chemo- and/or radiotherapy as the primary postoperative treatment. Follow-up data were available for 132 cases. After a median follow-up time of 1.5 years (range 0.2–25) across all patients, 1.5-year progression-free survival rates were 52±12% for GNTNI, 86±5% for PGNT, and 100% for RGNT. The 1.5-year overall-survival were 95±5%, 98±2%, and 100%, respectively. Conclusions: The clinical understanding of the three new entities of glioneuronal tumors, PGNT, RGNT and GNTNI, is currently emerging. The present meta-analysis will hopefully contribute to a delineation of their diagnostic, therapeutic, and prognostic profiles. However, the available data do not provide a solid basis to define the optimum treatment approach. Hence, a central register should be established.
- Andere Ausgabe
- Link zur Originalpublikation in der Zeitschrift PLoS ONE
Link: http://dx.doi.org/10.1038/cddis.2014.25 - Freie Schlagwörter (DE)
- Zentralnervensystem, Krebsdiagnostik, Krebsbehandlung, Metaanalyse
- Freie Schlagwörter (EN)
- Central nervous system, cancer detection and diagnosis, cancer treatment, meta-analysis
- Klassifikation (DDC)
- 610
- Herausgeber (Institution)
- Universität Leipzig
- Verlag
- Public Library of Science, San Francisco, Calif.
- Förder- / Projektangaben
- URN Qucosa
- urn:nbn:de:bsz:15-qucosa-148338
- Veröffentlichungsdatum Qucosa
- 11.07.2014
- Dokumenttyp
- Artikel
- Sprache des Dokumentes
- Englisch